Preventing High-Risk Adenomas and Second Cancers in Colon Cancer Survivors (S0820)
In this trial, people who have undergone curative surgery for stage 0-3 colon cancer, with or without adjuvant chemotherapy, will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months. Doctors will closely monitor all trial participants throughout the study to detect the recurrence of high-risk adenomas or the development of new colon or rectal cancers.
• S0820 Protocol
• Featured Clinical Trial Summary
• Information for Potential Participants (from SWOG)